Leveraging Metabolic-Driven Treatment Strategies to Target the Origins of NASH

Experts provide a review of therapeutic interventions for NAFLD/NASH, including key recommendations from the latest clinical care guidelines and the safety and efficacy of emerging agents.

Manal F. Abdelmalek, MD, MPH
Program Director Rohit Loomba, MD, MHSc Brent Tetri, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Registered Nurses: 1.5 Nursing contact hours Physician Assistants: 1.5 AAPA Category 1 CME Credits Released: December 7, 2022 Expired: No longer available for credit

Read my take on NASH heterogeneity and its implications for treatment.

Brent Tetri, MD Released: September 29, 2022

Those who treat patients with type 2 diabetes may encounter nonalcoholic fatty liver disease. See an expert’s summary of guideline-recommended management and how we can better care for these patients.

Rohit Loomba, MD, MHSc Released: January 4, 2023

An expert shares her take on emerging strategies for combination treatment for NAFLD and NASH with GLP-1 receptor agonists plus SGLT2 inhibitors.

Manal F. Abdelmalek, MD, MPH Released: February 2, 2023

In these unlocked downloadable slides, experts provide a review of therapeutic interventions for NAFLD/NASH including key recommendations from the latest clinical care guidelines and the safety and efficacy of emerging agents.

Manal F. Abdelmalek, MD, MPH
Program Director Rohit Loomba, MD, MHSc Brent Tetri, MD Released: November 4, 2022